An independent benchmark — peptide · GLP-1 · HRT · longevity
You make a go/no-go sourcing call on every reorder. Right now, you make it blind.
We're running the 2026 Supplier Risk Benchmark — an independent study of how peptide, GLP-1, HRT and longevity clinics actually source and verify what they put in patients. We're interviewing clinic operators now, and everyone who takes part sees the findings first.
Independent research. Not a pitch.
We're interviewing 50–70 clinic operators.
The benchmark is built from real conversations with the people who source and sign off on what goes into patients — what's painful today, what they'd want handled differently, and how they'd even know if a supplier went bad. Thirty minutes, confidential, and you see the findings before anyone else. It's research, not a pitch — if you run a peptide, GLP-1, HRT or longevity clinic, we want to hear from you.
A certificate of analysis is not due diligence. Most clinics find that out too late.
Compounded peptide and GLP-1 sourcing runs through a fast-moving, lightly-regulated supply chain. COAs get forged. Suppliers shut down overnight. And independent testing keeps finding the same thing.
When a sourcing decision goes wrong, the liability lands on the prescriber and the practice — not the supplier. The question a board, an insurer, or the FDA asks next is the hard one: can you document where every vial came from?
Six dimensions of supplier risk most clinics have never scored.
The interview maps how your practice actually handles sourcing today — not how it should, but what really happens — across the areas where exposure tends to hide.
Verification & monitoring
How you confirm what's in a vial, and whether you'd know if a supplier's quality or license changed after you onboarded them.
Documentation & regulatory awareness
What you could actually show a board, an insurer or the FDA — and how closely you track the enforcement landscape your suppliers sit in.
Incident readiness & exposure
What happens the day a supplier is flagged or vanishes — and how much personal and clinical risk rides on that single moment.
Take part and you get the industry benchmark — a confidential read on how your sourcing actually holds up, and how you compare with clinics like yours. You'll also be helping build the first independent service made to help clinics manage supplier risk in peptide and GLP-1 medicine. Every response stays anonymous; only aggregate findings are ever published.
Independence isn't a tagline here. It's the whole point.
No supplier, lab or pharmacy sponsors this benchmark, and no one can pay to score better or keep a finding quiet. We're not the FDA and we're not a regulator. The only job of the 2026 benchmark is to tell clinics the truth about how their supply chain actually holds up.
Who we're interviewing.
Owner-operated peptide, longevity & HRT clinics
Where the person who signs off on sourcing is the same person who carries the license and the liability. The exposure is personal, and the current process is a folder of PDFs and hope.
GLP-1 telehealth operators
Where the FDA has named due diligence on compounding pharmacies as a primary line of scrutiny — and where a single supplier failure becomes a board-level problem overnight.
Independent, and built to stay that way.
PeptEye was founded by Dan Oliveira, an independent researcher focused on supplier risk in clinical compounding. It has no supplier, lab or pharmacy behind it, and takes no money from the companies it studies. The 2026 Supplier Risk Benchmark is its first project — an independent read on how clinics actually source and verify what they put in patients.